Back

Kither doses first COPD patients in KIT2014 Phase 1b/2a trial

Verifying
  • Kither Biotech dosed the first patients in its KIT2014 COPD Phase 1b/2a trial.
  • 56 healthy participants previously received daily doses ranging from 0.1 mg to 2 mg.
  • Initial results from the Australian multicenter study are expected by Q1 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.